Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Vax2Muc

Financiado

Cerrado

NEXT GENERATION VACCINES AGAINST GASTROINTESTINAL MUCOSAL PATHOGENS, USING HELIC...

NEXT GENERATION VACCINES AGAINST GASTROINTESTINAL MUCOSAL PATHOGENS, USING HELICOBACTER PYLORI AS MODEL PATHOGEN To overcome antimicrobial resistance (AMR) compromising global public health, novel strategies to develop next generation vaccines against AMR pathogens are required. However, the development of effective vaccines is challenging f... ver más

30/06/2028

TUM

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

TECHNISCHE UNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-01

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the nex... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

TUM

Lider

Proyectos interesantes

CDVAX

Medical Technol...

Vaccinology

8M€ Cerrado

HELICOVAXOR

Medical Technol...

Biotechnology

2M€ Cerrado

PARAGON NOVEL VACCINE

Medical Technol...

Data Science

7M€ Cerrado

LABVLEISH

Medical Technol...

Public Health

219K€ Cerrado

CPP2021-008310

Medical Technol...

Data Science

395K€ Cerrado

RTI2018-097625-B-I00

Medical Technol...

Biotechnology

290K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 59 meses Fecha Inicio: 2023-07-01
Fecha Fin: 2028-06-30

Líder del proyecto

TECHNISCHE UNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto To overcome antimicrobial resistance (AMR) compromising global public health, novel strategies to develop next generation vaccines against AMR pathogens are required. However, the development of effective vaccines is challenging for bacterial infections occurring at mucosal sites, in particular in the gastrointestinal (GI) tract. In this context, H. pylori is listed as high priority AMR pathogen and the most common chronic bacterial infection affecting half of the world’s population with a high risk to progress into gastric cancer. Previous failures in H. pylori vaccine development approaches suggest that induction of mucosal immunity is required for protection. Thus, Vax2Muc will develop a rational prophylactic lead candidate against H. pylori in a straight-forward manner and directly evaluate this candidate for safety and immunogenicity in a phase I clinical trial, serving as proof-of-concept for novel vaccine technologies developed in Vax2Muc. To induce long-term protective mucosal immune responses sustained by tissue resident memory T cells, we will apply our previously identified vaccine antigens, combined with potent adjuvants for a systemic prime, and implemented in an innovative oro-mucosal film for a mucosal pull. Vax2Muc will further advance GMP manufacturing, and investigate and progress novel vaccine technologies and strategies tailored for mucosal application. We will evaluate our lead candidate and alternative approaches in pre-clinical mouse and pig models to define meaningful correlates of immunity and protection, which are still lacking for most of GI/AMR infections. Thus, Vax2Muc will deliver (i) a prophylactic vaccine candidate against H. pylori as PoC, and (ii) a wealth of knowledge and technologies that can be translated into the clinical development pipeline and are broadly applicable for various GI/AMR mucosal pathogens to significantly benefit the challenging field of mucosal vaccination and finally reduce disease burden from AMR/GI diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores